Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 3Terminated 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Crohn Disease 1Colitis, Ulcerative 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × vedolizumab × Clear all
NCT02768532 2023-06-15

VEDO-PREDIRESP

Centre Hospitalier Universitaire de Saint Etienne

Phase 4 Terminated
47 enrolled

Crohn Disease

NCT03802214 2020-12-21

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF(Tumor Necrosis Factor)Therapy

Stanford University

Terminated
1 enrolled

Colitis, Ulcerative

Data powered by HemOnc (CC BY 4.0) Colophon ⚡